Annie Luetkemeyer, MD

Title(s)Professor, Medicine
SchoolSchool of Medicine
Address2540 23rd Street, #4904
San Francisco CA 94110
Phone415-502-5753
ORCID ORCID Icon0000-0003-0911-1578 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, San Francisco2006 Advance Training in Clinical Research
    University of California, San Francisco, SFVAMC2003Internal Medicine
    University of California, San Francisco2002Internal Medicine
    University of California, San FranciscoFellowship2007Infectious Diseases
    Harvard Medical SchoolMD1999Medicine
    Stanford UniversityAB1994American Studies

    Collapse Overview 

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Academic Senate

    Collapse Featured Content 
    Collapse Twitter

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Long-term in vitro exposure of Treponema pallidum to sub-bactericidal doxycycline did not induce resistance: Implications for doxy-PEP and syphilis. J Infect Dis. 2024 Jul 27. Tantalo LC, Luetkemeyer A, Lieberman NAP, Nunley BE, Avendaño C, Greninger AL, Celum C, Giacani L. PMID: 39067061.
      View in: PubMed   Mentions:    Fields:    
    2. Long-term in vitro exposure of Treponema pallidum to sub-bactericidal doxycycline did not induce resistance: Implications for doxy-PEP and syphilis. bioRxiv. 2024 Jun 27. Tantalo LC, Luetkemeyer A, P Lieberman NA, Nunley BE, Avendaño C, Greninger AL, Celum C, Giacani L. PMID: 38979216; PMCID: PMC11230427.
      View in: PubMed   Mentions:
    3. Community-Based Point-of-Diagnosis Hepatitis C Treatment for Marginalized Populations: A Nonrandomized Controlled Trial. JAMA Netw Open. 2023 10 02; 6(10):e2338792. Morris MD, McDonell C, Luetkemeyer AF, Thawley R, McKinney J, Price JC. PMID: 37862013; PMCID: PMC10589813.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    4. Postexposure Doxycycline for Sexually Transmitted Infections. Reply. N Engl J Med. 2023 Jul 20; 389(3):286-287. Luetkemeyer AF, Cannon C, Celum C. PMID: 37467511.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    5. Evaluating Demographic Representation in Clinical Trials: Use of the Adaptive Coronavirus Disease 2019 Treatment Trial (ACTT) as a Test Case. Open Forum Infect Dis. 2023 Jun; 10(6):ofad290. Ortega-Villa AM, Hynes NA, Levine CB, Yang K, Wiley Z, Jilg N, Wang J, Whitaker JA, Colombo CJ, Nayak SU, Kim HJ, Iovine NM, Ince D, Cohen SH, Langer AJ, Wortham JM, Atmar RL, El Sahly HM, Jain MK, Mehta AK, Wolfe CR, Gomez CA, Beresnev T, Mularski RA, Paules CI, Kalil AC, Branche AR, Luetkemeyer A, Zingman BS, Voell J, Whitaker M, Harkins MS, Davey RT, Grossberg R, George SL, Tapson V, Short WR, Ghazaryan V, Benson CA, Dodd LE, Sweeney DA, Tomashek KM. PMID: 37383244; PMCID: PMC10296069.
      View in: PubMed   Mentions: 2  
    6. Bivalent and Monovalent SARS-CoV-2 Variant Vaccine Boosters Improve coverage of the known Antigenic Landscape: Results of the COVID-19 Variant Immunologic Landscape (COVAIL) Trial. Res Sq. 2023 May 05. Branche A, Rouphael N, Diemert D, Falsey A, Losada C, Baden LR, Frey S, Whitaker J, Little S, Anderson E, Walter E, Novak R, Rupp R, Jackson L, Babu T, Kottkamp A, Luetkemeyer A, Immergluck L, Presti R, Backer M, Winokur P, Mahgoub S, Goepfert P, Fusco D, Malkin E, Bethony J, Walsh E, Graciaa D, Samaha H, Sherman A, Walsh S, Abate G, Oikonomopoulou Z, El Sahly H, Martin T, Kamidani S, Smith M, Ladner B, Porterfield L, Dunstan M, Wald A, Davis T, Atmar R, Mulligan M, Lyke K, Posavad C, Meagher M, Stephens D, Neuzil K, Abebe K, Hill H, Albert J, Telu K, Mu J, Lewis T, Giebeig L, Eaton A, Netzl A, Wilks S, Tureli S, Makhene M, Crandon S, Montefiori D, Makowski M, Smith D, Nayak S, Roberts P, Beigel J. PMID: 37205592; PMCID: PMC10187423.
      View in: PubMed   Mentions:
    7. Association of Convalescent Plasma Treatment With Clinical Status in Patients Hospitalized With COVID-19: A Meta-analysis. JAMA Netw Open. 2022 01 04; 5(1):e2147331. Troxel AB, Petkova E, Goldfeld K, Liu M, Tarpey T, Wu Y, Wu D, Agarwal A, Avendaño-Solá C, Bainbridge E, Bar KJ, Devos T, Duarte RF, Gharbharan A, Hsue PY, Kumar G, Luetkemeyer AF, Meyfroidt G, Nicola AM, Mukherjee A, Ortigoza MB, Pirofski LA, Rijnders BJA, Rokx C, Sancho-Lopez A, Shaw P, Tebas P, Yoon HA, Grudzen C, Hochman J, Antman EM. PMID: 35076699; PMCID: PMC8790669.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCellsPHPublic Health
    8. Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med. 2020 11 05; 383(19):1813-1826. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh MD, Ruiz-Palacios GM, Benfield T, Fätkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC, ACTT-1 Study Group Members. PMID: 32445440; PMCID: PMC7262788.
      View in: PubMed   Mentions: 3055     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    9. Impact of a digital medicine programme on hepatitis C treatment adherence and efficacy in adults at high risk for non-adherence. Aliment Pharmacol Ther. 2020 06; 51(12):1384-1396. Sulkowski M, Luetkemeyer AF, Wyles DL, Martorell C, Muir A, Weisberg I, Gordon SC, McLain R, Huhn G. PMID: 32352586.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    10. Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals. Clin Infect Dis. 2019 07 18; 69(3):514-522. Naggie S, Fierer DS, Hughes MD, Kim AY, Luetkemeyer A, Vu V, Roa J, Rwema S, Brainard DM, McHutchison JG, Peters MG, Kiser JJ, Marks KM, Chung RT, Acquired Immunodeficiency Syndrome Clinical Trials Group (ACTG) A5327 Study Team. PMID: 31220220; PMCID: PMC6637278.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCellsCTClinical Trials
    11. A pilot metabolomics study of tuberculosis immune reconstitution inflammatory syndrome. Int J Infect Dis. 2019 Jul; 84:30-38. Silva CAM, Graham B, Webb K, Ashton LV, Harton M, Luetkemeyer AF, Bokatzian S, Almubarak R, Mahapatra S, Hovind L, Kendall MA, Havlir D, Belisle JT, De Groote MA. PMID: 31009738; PMCID: PMC6613934.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    12. Localized US Efforts to Eliminate Hepatitis C. Infect Dis Clin North Am. 2018 06; 32(2):293-311. Gaudino A, Gay B, Garmon C, Selick M, Vreeland R, Burk K, Huriaux E, Facente SN, Luetkemeyer A, Waters P, Graham CS. PMID: 29778257.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCellsPHPublic Health
    13. Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials. Liver Int. 2018 06; 38(6):1010-1021. Tam E, Luetkemeyer AF, Mantry PS, Satapathy SK, Ghali P, Kang M, Haubrich R, Shen X, Ni L, Camus G, Copans A, Rossaro L, Guyer B, Brown RS, RESCUE and ACTG A5348 study investigators. PMID: 29091342; PMCID: PMC5930158.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    14. Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failure. Hepatology. 2017 12; 66(6):1794-1804. Wyles D, Wedemeyer H, Ben-Ari Z, Gane EJ, Hansen JB, Jacobson IM, Laursen AL, Luetkemeyer A, Nahass R, Pianko S, Zeuzem S, Jumes P, Huang HC, Butterton J, Robertson M, Wahl J, Barr E, Joeng HK, Martin E, Serfaty L, C-CREST Part C and C-SURGE Investigators. PMID: 28688129.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    15. Disabling Dactylitis and Tenosynovitis Due to Mycobacterium haemophilum in a Patient With Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome. Open Forum Infect Dis. 2017; 4(3):ofx165. Woodworth MH, Marquez C, Chambers H, Luetkemeyer A. PMID: 28959701; PMCID: PMC5610725.
      View in: PubMed   Mentions: 3  
    16. Impact of Larger Sputum Volume on Xpert® MTB/RIF Assay Detection of Mycobacterium tuberculosis in Smear-Negative Individuals with Suspected Tuberculosis. J Clin Med. 2017 Aug 07; 6(8). Badal-Faesen S, Firnhaber C, Kendall MA, Wu X, Grinsztejn B, Escada RODS, Fernandez M, Hogg E, Sanne I, Johnson P, Alland D, Mazurek GH, Benator DA, Luetkemeyer AF, AIDS Clinical Trials Group A5295, Tuberculosis Trials Consortium Study 34 Teams. PMID: 28783093; PMCID: PMC5575580.
      View in: PubMed   Mentions: 4  
    17. Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2. Open Forum Infect Dis. 2017; 4(3):ofx154. Rockstroh JK, Orkin C, Viani RM, Wyles D, Luetkemeyer AF, Lazzarin A, Soto-Malave R, Nelson MR, Bhagani SR, Klinker HHF, Rizzardini G, Girard PM, Tural C, Shulman NS, Mobashery N, Hu YB, Fredrick LM, Pilot-Matias T, Trinh R, Gane E. PMID: 28948180; PMCID: PMC5597897.
      View in: PubMed   Mentions: 8  
    18. Understanding Hepatitis C Virus Drug Resistance: Clinical Implications for Current and Future Regimens. Top Antivir Med. 2017 Jul/Aug; 25(3):103-109. Wyles DL, Luetkemeyer AF. PMID: 28820725; PMCID: PMC5935211.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCells
    19. Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study. Clin Infect Dis. 2017 Jul 01; 65(1):6-12. Wyles D, Bräu N, Kottilil S, Daar ES, Ruane P, Workowski K, Luetkemeyer A, Adeyemi O, Kim AY, Doehle B, Huang KC, Mogalian E, Osinusi A, McNally J, Brainard DM, McHutchison JG, Naggie S, Sulkowski M, ASTRAL-5 Investigators. PMID: 28369210; PMCID: PMC6248627.
      View in: PubMed   Mentions: 60     Fields:    Translation:HumansCTClinical Trials
    20. CROI 2017: Highlights of Advances in Viral Hepatitis and Liver Fibrosis. Top Antivir Med. 2017 May/Jun; 25(2):84-92. Luetkemeyer AF, Wyles DL. PMID: 28598793; PMCID: PMC5677046.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    21. Safety and Efficacy of Pegylated Interferon Lambda, Ribavirin, and Daclatasvir in HCV and HIV-Coinfected Patients. J Interferon Cytokine Res. 2017 03; 37(3):103-111. Nelson M, Rubio R, Lazzarin A, Romanova S, Luetkemeyer A, Conway B, Molina JM, Xu D, Srinivasan S, Portsmouth S. PMID: 28282271.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCellsCTClinical Trials
    22. Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial. Ann Intern Med. 2016 11 01; 165(9):625-634. Dore GJ, Altice F, Litwin AH, Dalgard O, Gane EJ, Shibolet O, Luetkemeyer A, Nahass R, Peng CY, Conway B, Grebely J, Howe AY, Gendrano IN, Chen E, Huang HC, Dutko FJ, Nickle DC, Nguyen BY, Wahl J, Barr E, Robertson MN, Platt HL, C-EDGE CO-STAR Study Group. PMID: 27537841.
      View in: PubMed   Mentions: 155     Fields:    Translation:Humans
    23. Tuberculosis Therapy Modifies the Cytokine Profile, Maturation State, and Expression of Inhibitory Molecules on Mycobacterium tuberculosis-Specific CD4+ T-Cells. PLoS One. 2016; 11(7):e0158262. Saharia KK, Petrovas C, Ferrando-Martinez S, Leal M, Luque R, Ive P, Luetkemeyer A, Havlir D, Koup RA. PMID: 27367521; PMCID: PMC4930205.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    24. A survey of tuberculosis infection control practices at the NIH/NIAID/DAIDS-supported clinical trial sites in low and middle income countries. BMC Infect Dis. 2016 06 10; 16:269. Godfrey C, Tauscher G, Hunsberger S, Austin M, Scott L, Schouten JT, Luetkemeyer AF, Benson C, Coombs R, Swindells S, HIV Network Coordinating (HANC) TB Diagnostic Laboratory Working Division of AIDS, National Institut. PMID: 27287374; PMCID: PMC4901412.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCellsPHPublic Health
    25. CROI 2016: Viral Hepatitis and Liver Fibrosis. Top Antivir Med. 2016 May-Jun; 24(1):47-58. Luetkemeyer AF, Wyles DL. PMID: 27398862; PMCID: PMC6148925.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    26. Tuberculosis Infection in Early Childhood and the Association with HIV-exposure in HIV-uninfected Children in Rural Uganda. Pediatr Infect Dis J. 2016 May; 35(5):524-9. Marquez C, Chamie G, Achan J, Luetkemeyer AF, Kyohere M, Okiring J, Dorsey G, Kamya MR, Charlebois ED, Havlir DV. PMID: 26771662; PMCID: PMC4829461.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansPHPublic Health
    27. 12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens. Clin Infect Dis. 2016 06 15; 62(12):1489-96. Luetkemeyer AF, McDonald C, Ramgopal M, Noviello S, Bhore R, Ackerman P. PMID: 27025835; PMCID: PMC4885650.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCells
    28. Evaluation of Xpert MTB/RIF Versus AFB Smear and Culture to Identify Pulmonary Tuberculosis in Patients With Suspected Tuberculosis From Low and Higher Prevalence Settings. Clin Infect Dis. 2016 May 01; 62(9):1081-8. Luetkemeyer AF, Firnhaber C, Kendall MA, Wu X, Mazurek GH, Benator DA, Arduino R, Fernandez M, Guy E, Johnson P, Metchock B, Sattler F, Telzak E, Wang YF, Weiner M, Swindells S, Sanne IM, Havlir DV, Grinsztejn B, Alland D, AIDS Clinical Trials Group A5295 and Tuberculosis Trials Consortium Study 34 Teams. PMID: 26839383; PMCID: PMC4826450.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCells
    29. The Safety and Immunogenicity of an Interleukin-12-Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection. J Acquir Immune Defic Syndr. 2016 Feb 01; 71(2):163-71. Jacobson JM, Zheng L, Wilson CC, Tebas P, Matining RM, Egan MA, Eldridge J, Landay AL, Clifford DB, Luetkemeyer AF, Tiu J, Martinez AL, Janik J, Spitz TA, Hural J, McElrath J, Frahm N, ACTG A5281 Protocol Team. PMID: 26761518; PMCID: PMC4712745.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCellsCTClinical Trials
    30. Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med. 2015 Aug 20; 373(8):714-25. Wyles DL, Ruane PJ, Sulkowski MS, Dieterich D, Luetkemeyer A, Morgan TR, Sherman KE, Dretler R, Fishbein D, Gathe JC, Henn S, Hinestrosa F, Huynh C, McDonald C, Mills A, Overton ET, Ramgopal M, Rashbaum B, Ray G, Scarsella A, Yozviak J, McPhee F, Liu Z, Hughes E, Yin PD, Noviello S, Ackerman P, ALLY-2 Investigators. PMID: 26196502.
      View in: PubMed   Mentions: 153     Fields:    Translation:HumansCells
    31. Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med. 2015 Aug 20; 373(8):705-13. Naggie S, Cooper C, Saag M, Workowski K, Ruane P, Towner WJ, Marks K, Luetkemeyer A, Baden RP, Sax PE, Gane E, Santana-Bagur J, Stamm LM, Yang JC, German P, Dvory-Sobol H, Ni L, Pang PS, McHutchison JG, Stedman CA, Morales-Ramirez JO, Bräu N, Jayaweera D, Colson AE, Tebas P, Wong DK, Dieterich D, Sulkowski M, ION-4 Investigators. PMID: 26196665; PMCID: PMC4892372.
      View in: PubMed   Mentions: 189     Fields:    Translation:HumansCellsCTClinical Trials
    32. Bartonella quintana Aortitis in a Man with AIDS, Diagnosed by Needle Biopsy and 16S rRNA Gene Amplification. J Clin Microbiol. 2015 Aug; 53(8):2773-6. Lee SA, Plett SK, Luetkemeyer AF, Borgo GM, Ohliger MA, Conrad MB, Cookson BT, Sengupta DJ, Koehler JE. PMID: 26063867; PMCID: PMC4508458.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    33. CROI 2015: Highlights of Viral Hepatitis Therapy. Top Antivir Med. 2015 Mar-Apr; 23(1):66-76. Luetkemeyer AF, Wyles DL. PMID: 25965313; PMCID: PMC6148900.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    34. Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study. Clin Infect Dis. 2015 Jun 15; 60(12):1860-3. Luetkemeyer AF, Rosenkranz SL, Lu D, Grinsztejn B, Sanchez J, Ssemmanda M, Sanne I, McIlleron H, Havlir DV, Haas DW, Adult AIDS Clinical Trials Group A5221 and A5243 Study Teams. PMID: 25722197; PMCID: PMC4542662.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    35. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA. 2014 Jul 23-30; 312(4):353-61. Sulkowski MS, Naggie S, Lalezari J, Fessel WJ, Mounzer K, Shuhart M, Luetkemeyer AF, Asmuth D, Gaggar A, Ni L, Svarovskaia E, Brainard DM, Symonds WT, Subramanian GM, McHutchison JG, Rodriguez-Torres M, Dieterich D, PHOTON-1 Investigators. PMID: 25038354; PMCID: PMC4997358.
      View in: PubMed   Mentions: 90     Fields:    Translation:HumansCellsCTClinical Trials
    36. Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin. Antimicrob Agents Chemother. 2014 Sep; 58(9):5245-52. Dooley KE, Luetkemeyer AF, Park JG, Allen R, Cramer Y, Murray S, Sutherland D, Aweeka F, Koletar SL, Marzan F, Bao J, Savic R, Haas DW, AIDS Clinical Trials Group A5306 Study Team. PMID: 24957823; PMCID: PMC4135849.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCTClinical Trials
    37. CROI 2014: Viral hepatitis and complications of HIV disease and antiretroviral therapy. Top Antivir Med. 2014 May; 22(2):602-15. Luetkemeyer AF, Havlir DV, Currier JS. PMID: 24901886; PMCID: PMC6148912.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    38. HIV-associated central nervous system tuberculosis. Semin Neurol. 2014 Feb; 34(1):103-15. Chamie G, Marquez C, Luetkemeyer A. PMID: 24715493.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    39. Tuberculosis immune reconstitution inflammatory syndrome in A5221 STRIDE: timing, severity, and implications for HIV-TB programs. J Acquir Immune Defic Syndr. 2014 Apr 01; 65(4):423-8. Luetkemeyer AF, Kendall MA, Nyirenda M, Wu X, Ive P, Benson CA, Andersen JW, Swindells S, Sanne IM, Havlir DV, Kumwenda J, Adult AIDS Clinical Trials Group A5221 Study Team. PMID: 24226057; PMCID: PMC3943693.
      View in: PubMed   Mentions: 43     Fields:    Translation:Humans
    40. Pilot study of pioglitazone before HCV retreatment in HIV/HCV genotype 1-infected subjects with insulin resistance and previous nonresponse to peginterferon and ribavirin therapy: A5239. J Acquir Immune Defic Syndr. 2014 Mar 01; 65(3):345-9. Marks KM, Kitch D, Chung RT, Hadigan C, Andersen J, Tien P, Luetkemeyer A, Alston-Smith B, Glesby MJ, A5239 Team. PMID: 24525470; PMCID: PMC3998202.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCellsCTClinical Trials
    41. Evaluation of two line probe assays for rapid detection of Mycobacterium tuberculosis, tuberculosis (TB) drug resistance, and non-TB Mycobacteria in HIV-infected individuals with suspected TB. J Clin Microbiol. 2014 Apr; 52(4):1052-9. Luetkemeyer AF, Kendall MA, Wu X, Lourenço MC, Jentsch U, Swindells S, Qasba SS, Sanchez J, Havlir DV, Grinsztejn B, Sanne IM, Firnhaber C, Adult AIDS Clinical Trials Group A5255 Study Team. PMID: 24430455; PMCID: PMC3993501.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    42. Addition of nitazoxanide to PEG-IFN and ribavirin to improve HCV treatment response in HIV-1 and HCV genotype 1 coinfected persons naïve to HCV therapy: results of the ACTG A5269 trial. HIV Clin Trials. 2013 Nov-Dec; 14(6):274-83. Amorosa VK, Luetkemeyer A, Kang M, Johnson VA, Umbleja T, Haas DW, Yesmin S, Bardin MC, Chung RT, Alston-Smith B, Tebas P, Peters MG. PMID: 24334180; PMCID: PMC4113390.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    43. Household ventilation and tuberculosis transmission in Kampala, Uganda. Int J Tuberc Lung Dis. 2013 Jun; 17(6):764-70. Chamie G, Wandera B, Luetkemeyer A, Bogere J, Mugerwa RD, Havlir DV, Charlebois ED. PMID: 23676159.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    44. Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study. Clin Infect Dis. 2013 Aug; 57(4):586-93. Luetkemeyer AF, Rosenkranz SL, Lu D, Marzan F, Ive P, Hogg E, Swindells S, Benson CA, Grinsztejn B, Sanne IM, Havlir DV, Aweeka F, Adult AIDS Clinical Trials Group A5221 Study Team. PMID: 23592830; PMCID: PMC3719885.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    45. CROI 2013: Complications of HIV disease, viral hepatitis, and antiretroviral therapy. Top Antivir Med. 2013 Apr-May; 21(2):62-74. Luetkemeyer AF, Havlir DV, Currier JS. PMID: 23681961; PMCID: PMC6148869.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    46. Complications of HIV disease and antiretroviral therapy. Top Antivir Med. 2012 Jun-Jul; 20(2):48-60. Luetkemeyer AF, Havlir DV, Currier JS. PMID: 22710907; PMCID: PMC6148866.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    47. Resistance patterns and response to entecavir intensification among HIV-HBV-coinfected adults with persistent HBV viremia. J Acquir Immune Defic Syndr. 2011 Nov 01; 58(3):e96-9. Luetkemeyer AF, Charlebois ED, Hare CB, Black D, Smith A, Havlir DV, Peters MG. PMID: 22005002; PMCID: PMC4120944.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    48. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011 Oct 20; 365(16):1482-91. Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS, Luetkemeyer AF, Hogg E, Rooney JF, Wu X, Hosseinipour MC, Lalloo U, Veloso VG, Some FF, Kumarasamy N, Padayatchi N, Santos BR, Reid S, Hakim J, Mohapi L, Mugyenyi P, Sanchez J, Lama JR, Pape JW, Sanchez A, Asmelash A, Moko E, Sawe F, Andersen J, Sanne I, AIDS Clinical Trials Group Study A5221. PMID: 22010914; PMCID: PMC3327101.
      View in: PubMed   Mentions: 275     Fields:    Translation:HumansCells
    49. CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap. Am J Respir Crit Care Med. 2011 Oct 15; 184(8):972-9. Nahid P, Saukkonen J, Mac Kenzie WR, Johnson JL, Phillips PP, Andersen J, Bliven-Sizemore E, Belisle JT, Boom WH, Luetkemeyer A, Campbell TB, Eisenach KD, Hafner R, Lennox JL, Makhene M, Swindells S, Villarino ME, Weiner M, Benson C, Burman W, National Institutes of Health, Centers for Disease Control and Prevention. PMID: 21737585; PMCID: PMC3208659.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    50. Tuberculosis drug development: ensuring people living with HIV are not left behind. Am J Respir Crit Care Med. 2011 Nov 15; 184(10):1107-13. Luetkemeyer AF, Getahun H, Chamie G, Lienhardt C, Havlir DV. PMID: 21868507; PMCID: PMC3361323.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    51. Complications of HIV disease and antiretroviral therapy. Top Antivir Med. 2011 May-Jun; 19(2):58-68. Luetkemeyer AF, Havlir DV, Currier JS. PMID: 21868823; PMCID: PMC6148948.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    52. Significant variation in presentation of pulmonary tuberculosis across a high resolution of CD4 strata. Int J Tuberc Lung Dis. 2010 Oct; 14(10):1295-302. Chamie G, Luetkemeyer A, Walusimbi-Nanteza M, Okwera A, Whalen CC, Mugerwa RD, Havlir DV, Charlebois ED. PMID: 20843421; PMCID: PMC3033769.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansCells
    53. Current issues in the diagnosis and management of tuberculosis and HIV coinfection in the United States. Top HIV Med. 2010 Oct-Nov; 18(4):143-8. Luetkemeyer AF. PMID: 21107014.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    54. Tuberculosis as part of the natural history of HIV infection in developing countries. Clin Infect Dis. 2010 May 15; 50 Suppl 3:S245-54. Chamie G, Luetkemeyer A, Charlebois E, Havlir DV. PMID: 20397955; PMCID: PMC3032796.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansPHPublic Health
    55. Complications of HIV disease and antiretroviral treatment. Top HIV Med. 2010 Apr-May; 18(2):57-65. Luetkemeyer AF, Havlir DV, Currier JS. PMID: 20516525; PMCID: PMC3032798.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    56. Comparison of an interferon-gamma release assay with tuberculin skin testing in HIV-infected individuals. Am J Respir Crit Care Med. 2007 Apr 01; 175(7):737-42. Luetkemeyer AF, Charlebois ED, Flores LL, Bangsberg DR, Deeks SG, Martin JN, Havlir DV. PMID: 17218620; PMCID: PMC1899289.
      View in: PubMed   Mentions: 59     Fields:    Translation:HumansCTClinical Trials
    57. Antiretroviral therapy and TB. Trop Doct. 2006 Apr; 36(2):73-9. Swaminathan S, Luetkemeyer A, Srikantiah P, Lin R, Charlebois E, Havlir DV. PMID: 16611437.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    58. Clinical presentation and course of acute hepatitis C infection in HIV-infected patients. J Acquir Immune Defic Syndr. 2006 Jan 01; 41(1):31-6. Luetkemeyer A, Hare CB, Stansell J, Tien PC, Charlesbois E, Lum P, Havlir D, Peters M. PMID: 16340470; PMCID: PMC4050666.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCells
    59. Willing and able? Provision of medication for abortion by future internists. Womens Health Issues. 2005 Jan-Feb; 15(1):39-44. Schwarz EB, Luetkemeyer A, Foster DG, Weitz TA, Lindes D, Stewart FH. PMID: 15661586.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    Annie's Networks
    Concepts (244)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (36)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-6-g69de2244 on PROFILES-PWEB04.

    Copyright © The Regents of the University of California.